Mar 05, 2019 - Merck (MRK) gets CHMP recommendation for a six-week dosing schedule of Keytruda across all current monotherapy indications.
Mar 04, 2019 - AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.
Mar 01, 2019 - Spectrum Pharma (SPPI) misses bottom-line estimates in the fourth quarter but beats on revenues.
Feb 25, 2019 - Roche (RHHBY) to acquire Philadelphia-based gene therapy company, Spark Therapeutics, Inc. (ONCE) at a price of $114.50 per share in an all-cash transaction.
Feb 22, 2019 - Amgen (AMGN) and partners started enrollment for the second phase III study of omecamtiv mecarbil, which is being developed for the potential treatment of heart failure with reduced ejection fraction.
Feb 21, 2019 - The Zacks Analyst Blog Highlights: Walmart, Amgen, Honda, TransCanada and TransUnion
Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Feb 20, 2019 - Top Analyst Reports for Walmart, Amgen and Honda
Feb 20, 2019 - Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Feb 19, 2019 - The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.